Kristen Kramlich
Optometrist · Sioux Falls, SDNPI 1427408798
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), consulting fees and gifts — rather than concentrated in one kind of arrangement. Johnson & Johnson Vision Care, Inc. accounts for 61.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $2,635 and has fallen 89.4% since, to $279 in 2025. Among optometrist clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $53.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Bausch & Lomb Americas Inc.$549
- Alcon$530
- Plexus Optix, Inc.$144
- Novartis$138
- Tarsus Pharmaceuticals, Inc.$78
- plus $184 from 6 others
What the payments were for
- Consulting fees$2,02548%
- Food & beverage$2,19552%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 21 | $2,617 |
| Bausch & Lomb Americas Inc. | 15 | $549 |
| Alcon | 21 | $530 |
| Plexus Optix, Inc. | 3 | $144 |
| Novartis | 5 | $138 |
| Tarsus Pharmaceuticals, Inc. | 4 | $78 |
| Sun Pharmaceutical Industries Inc. | 4 | $62 |
| Oyster Point Pharma, Inc. | 1 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Biotissue Holdings Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$2,273
- BIOTRUE$241
- INFUSE$241
- TOTAL30$146
- AcrySof IQ PanOptix UV IOL$117
- Precision7$106
How this compares
$4,239 in reported general payments places this provider in the 90th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $48,457 |
| XdemvyLotilaner | 19 | $36,303 |
| XiidraLifitegrast | 16 | $10,619 |
| Cyclosporine | 25 | $8,845 |
| Brimonidine Tartrate | 13 | $4,418 |
| VyzultaLatanoprostene Bunod | 13 | $4,050 |
| Latanoprost | 129 | $1,153 |
| Timolol Maleate | 75 | $641 |
| Fluorometholone | 13 | $584 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $544 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $260 |
| ErythromycinErythromycin Base | 13 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $15 | $48,45749 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $78 | $36,30319 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $549 | $14,66929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 206 optometrist providers in South Dakota.
Other optometrist in Sioux Falls
- Justin SchweitzerSioux Falls$753K
- Mitchel IbachSioux Falls$395K
- Jason SchmitSioux Falls$79K
- Jeffery SaylerSioux Falls$8K
- Kayla KarpukSioux Falls$6K
- Travis LehrSioux Falls$5K
- Matthew ClarkeSioux Falls$5K
- Ryan HaiarSioux Falls$4K
- Joshua TimsSioux Falls$4K
- Larae ZimprichSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.